Disruption of Bile Acid Metabolism in the Gut–Liver Axis Predisposes Mice to Inflammatory Bowel Disease
MedComm · 2025-10 · 6 (10)
DOI: 10.1002/mco2.70429 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 09.10.2025. Verfasst von Hui Chang und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences and Department of Genetic and Metabolic Disease The Children's Hospital Zhejiang University School of Medicine National Clin…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Zhejiang Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that is frequently associated with inflammatory bowel disease (IBD). However, the precise mechanisms linking these conditions remain unclear. In this study, we established a murine model of experimental sclerosing cholangitis (eSC) using a DDC (3,5‐diethoxycarbonyl 1,4‐dihydrocollidine) diet. We then demonstrated that eSC mice exhibited increased susceptibility to DSS‐induced colitis, accompanied by severe intestinal pathology. Further integrated analyses revealed that eSC disrupted bile acid metabolism and gut microbiota composition, notably increasing Th17‐inducing bacteria and altering bile acid profiles. Single‐cell and bulk RNA‐seq analyses identified a marked expansion of colonic Th17 cells and a loss of immune homeostasis in eSC mice. Therapeutically, rectal administration of lithocholic acid (LCA) and its derivative, 3‐Oxo‐5β‐cholanoic acid (3‐O‐LCA), was found to restore farnesoid X receptor (FXR) signaling, reduce Th17 cell proportions, and alleviate liver and intestinal injury. Mechanistic studies show that LCA and 3‐O‐LCA modulate macrophage polarization and Th17 differentiation via FXR. These findings highlight the central role of the gut–liver axis, bile acid signaling, and Th17 responses in PSC–IBD pathogenesis, and suggest that targeting bile acid metabolism offers a promising therapeutic strategy. This work advances our understanding of PSC–IBD and provides a foundation for novel interventions in high‐risk patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Life Sciences and Department of Genetic and Metabolic Disease The Children's Hospital Zhejiang University School of Medicine National Clinical Research Center for Child Health Zhejiang University Hangzhou Chi…
- College of Pharmaceutical Sciences Zhejiang University Hangzhou China.
- Reproductive Medical Center The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China.
- Institute For Cell-Based Drug Development of Zhejiang Province Hangzhou China.
- Institute of Basic Medical Sciences Chinese Academy of Medical Sciences School of Basic Medicine Peking Union Medical College Beijing China.
ORCID-Profile: Mingyang Chen, Ye Chen
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Zhejiang Province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Chang, H., Jiang, Y., Zhao, Q., Su, Z., Chen, M., He, Q., Lai, J., Jiang, Y., Zheng, J., Pan, R., Shao, J., Zhao, R. C., & Chen, Y. (2025). Disruption of Bile Acid Metabolism in the Gut–Liver Axis Predisposes Mice to Inflammatory Bowel Disease. MedComm, 6(10). https://doi.org/10.1002/mco2.70429
Vancouver
Chang H, Jiang Y, Zhao Q, Su Z, Chen M, He Q, et al. Disruption of Bile Acid Metabolism in the Gut–Liver Axis Predisposes Mice to Inflammatory Bowel Disease. MedComm. 2025;6(10). doi:10.1002/mco2.70429
BibTeX
@article{Chang2025,
author = {Chang, Hui and Jiang, Yang and Zhao, Qiong and Su, Zhen and Chen, Mingyang and He, Qiufen and Lai, Jingbo and Jiang, Yingru and Zheng, Jing and Pan, Ruolang and Shao, Jianzhong and Zhao, Robert Chunhua and Chen, Ye},
title = {Disruption of Bile Acid Metabolism in the Gut–Liver Axis Predisposes Mice to Inflammatory Bowel Disease},
journal = {MedComm},
year = {2025},
volume = {6},
number = {10},
doi = {10.1002/mco2.70429}
}
EUVIMED